tbuckley/cabot-search huggingface dataset:
P276 Development of patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF)
Authors: AM Russell, S Sonecha, A Datta, R Hewitt, I Howell, A Elliott, M Wickremasinghe
Journal: Thorax (2016)

<h3>Background</h3> Research into patient experiences of living with IPF has increased. A key challenge is how to use this data intelligently to enable commissioners and providers to improve the quality of services delivered to this group of patients. This project aims to develop an IPF-PREM informed by patients' perceptions of their healthcare experiences. The IPF-PREM is underpinned by the NHS Patient Experience Framework (NPEF);<sup>1</sup> National Institute for Health and Care Excellence (NICE) Quality Standards (QS15 and 79) and aligned to national initiatives integrating Patient Reported Outcome Measures (PROMs) and PREMs into NHS care. <h3>Methods</h3> A scoping exercise was undertaken with patients diagnosed with IPF on their journey through the healthcare system covering eight areas corresponding to the NPEF.<sup>1</sup> Twenty patients representing all stages of the disease trajectory participated in one of three focus groups. Transcripts underwent content and thematic analysis. Patient preferences were also sought on questionnaire design. <h3>Results</h3> A number of key themes emerged. See Table 1. Of particular importance were issues concerning access: to specialist centres, medication and primary care services; consistency of care to prevent confusion; coordination of care especially for patients with multi-morbidities and getting the right information at the right time in the right way. Information enabling practical self-management was highly valued. Overarching was the need for continuity of care close to home. Participants valued having a nurse to co-ordinate care and to talk to at <i>all s</i>tages of the care pathway. The response categories patients were keen to avoid were visual images such as smiley faces. <h3>Conclusions</h3> The IPF-PREM will provide a valuable quality indicator for IPF service delivery at all stages of the disease trajectory complementing IPF PROMs. Implementation of the PREM will enable commissioners and providers to improve the quality of the services and the patient experience of care delivered across the wider inter-disciplinary team. <h3>Reference</h3> DH 2011 NHS Patient Experience Framework.
An epigenome-wide association study of total serum IgE in Hispanic children
Authors: Wei Chen, Ting Wang, Maria Pino-Yanes, Erick Forno, Liming Liang, Qi Yan, Donglei Hu, Daniel E. Weeks, Andrea Baccarelli, Edna Acosta-Perez, Celeste Eng, Yueh-Ying Han, Nadia Boutaoui, Catherine Laprise, Gwyneth A. Davies, Julian M. Hopkin, Miriam F. Moffatt, William O.C.M. Cookson, Glorisa Canino, Esteban G. Burchard, Juan C. Celedón
Journal: Journal of Allergy and Clinical Immunology (2017)
Feasibility of performing esophageal endoscopic submucosal dissection using master and slave transluminal endoscopic robot
Authors: Nobuyoshi Takeshita, Khek Ho, Soo Phee, Jennie Wong, Philip Chiu
Journal: Endoscopy (2017)

The feasibility of endoscopic submucosal dissection (ESD) using the master and slave transluminal endoscopic robot (MASTER) has been shown in our previous studies [1] [2] [3]. Compared with gastric ESD, esophageal ESD remains challenging because of technical difficulties and risks [4] [5]. The aim of this study was to evaluate the feasibility of using MASTER to perform esophageal ESD.
Clonal Evolution of Gene Mutations Involving DNA Methylation in the Progression of CMML to Secondary AML
Authors: Hsiao-Wen Kao, Ming-Chung Kuo, Po-Nan Wang, Jin-Hou Wu, Tung-Huei Lin, Yu-Shu Shih, Der-Cherng Liang, Lee-Yung Shih
Journal: Blood (2015)
NPM-ALK Converts JUNB from a Tumor Suppressor to an Oncogene.
Authors: Paul Vesely, Philipp B. Staber, Rene Ott, Montserrat Pinent, Werner Linkesch, Silvia Schauer, Andelko Hrzenjak, Marshall E. Kadin, David W. Sternberg, Gerald Hoefler
Journal: Blood (2006)
P145 Evaluation and quantification of treatment preferences for patients with asthma or copd using discrete choice experiment surveys
Authors: H Svedsater, E Hilton, D Leather, T Robinson, L Bradshaw, H Doll, B Nafees
Journal: Thorax (2016)

<h3>Background</h3> The impact of asthma and chronic obstructive pulmonary disease (COPD) on patients’ lives can be substantial, despite the use of maintenance medication. To understand the treatment preferences of patients with asthma or COPD, a discrete choice experiment (DCE) survey was developed, based on factors identified in a previous stage of this study as being influential.<sup>1</sup> <h3>Methods</h3> UK residents aged ≥18 years currently receiving treatment for asthma or COPD were recruited by a commercial recruitment panel (Global Perspectives) to take part in an internet-based survey. Participants provided demographic information and ranked eight attributes of treatment using an 8-point Likert scale (0 = extremely important–8 = not at all important). Furthermore, treatment preferences were elicited by a DCE survey; participants chose between two hypothetical treatments that differed in terms of previously identified influential attributes.<sup>1</sup> A mixed logit regression model assessed DCE preferences for each condition separately. <h3>Results</h3> Data were collected from 302 participants, who generally had poorly controlled asthma (indicated by Asthma Control Test™ scores ≤19/25) or experienced a high impact of COPD (indicated by COPD Assessment Test™ scores &gt;20/40) and had been living with asthma or COPD for approximately 23.4/8.5 years (Table). Most attributes of participants’ current treatment were similar for the asthma and COPD populations; participants ranked having well-controlled symptoms all day as most important while the monthly cost was ranked as least important (Table). Treatment preferences from most to least important (with some degree of variation between conditions) were: reduced sleep disturbance, inexpensive, easy/convenient to use, reduced flare ups/exacerbations, enabled participation in all desired physical activities, controlled symptoms all day, enabled participation in all desired social activities and reduced medication frequency (Table); all attributes were significant in influencing treatment choices. <h3>Conclusions</h3> All identified valued attributes of medications had a significant impact in the DCE, despite differences in relative importance, and should be considered by healthcare professionals when discussing maintenance treatment options with patients with asthma and COPD. These factors should be considered in the development of future medications. <h3>Reference</h3> Svedsater, <i>et al</i>. <i>AJRCCM</i> 2016;A1747.
Hereditary Protein S Type III Deficiency Is Not a Risk Factor for Venous and Arterial Thrombosis, in Contrast to Protein S Deficiency Type I. Results from a Family Cohort Study To Assess the Clinical Impact of a Laboratory Based Classification.
Authors: Jan-Leendert P. Brouwer, Nic J.G.M. Veeger, Wim van der Schaaf, Hanneke C. Kluin-Nelemans, Jan van der Meer
Journal: Blood (2004)
P1.05-005 Programmed Death-Ligand 1 (PD-L1) in Resected Lung Adenocarcinomas (LA) in a University Hospital
Authors: María Álvarez, Sandra Vicente, Ana Cebollero, Isabel Pajares, Esther Millastre, Jorge Hernando, Teresa Puértolas, Ramiro Álvarez, Miguel Artal Cortés, Antonio Antón
Journal: Journal of Thoracic Oncology (2017)
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients
Authors: Antonio Palumbo, Alessandra Larocca, Sonja Zweegman, Giulia Lupparelli, Agostina Siniscalchi, Pellegrino Musto, Moshe Levin, Henk Lokhorst, Sara Grammatico, Lucio Catalano, Roberto Ria, Anna Marina Liberati, Francesca Patriarca, Giulia Benevolo, Antonietta Pia Falcone, Bronno van der Holt, Sylvia Verelst, Davide Rossi, Claudia Crippa, Sara Bringhen, Roman Hajek, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld
Journal: Blood (2011)
Double-balloon enteroscopy-assisted ERCP in situs inversus with Roux-en-Y hepaticojejunostomy for complex anastomotic stricture dilated with Soehendra stent retriever
Authors: Tadahisa Inoue, Takaya Yamamoto, Norimitsu Ishii, Yuji Kobayashi, Kiyoaki Ito, Masashi Yoneda
Journal: Endoscopy (2017)

A woman in her 50s with situs inversus presented to our hospital with high fever, jaundice, and pain in the left hypochondriac region. The patient had undergone Roux-en-Y hepaticojejunostomy following iatrogenic bile duct injury during cholecystectomy 9 years earlier. Abdominal computed tomography and magnetic resonance cholangiopancreatography revealed bile duct dilatation, with areas suspicious for stenosis at the hepaticojejunostomy anastomosis, with the visceral organs in a mirror image location from their normal positions ([Fig. 1], [Fig. 2]). We diagnosed obstructive jaundice with cholangitis, and performed endoscopic retrograde cholangiopancreatography (ERCP) for biliary drainage using double-balloon enteroscopy (EI-580BT; Fujifilm, Tokyo, Japan).
P2.05-030 WBRT Prior EGFR TKIs is Effective Treatment Option for NSCLC Patients with CNS Metastases Harboring EGFR Mutation
Authors: Pawel Krawczyk, Marcin Nicoś, Dariusz Kowalski, Rodryg Ramlau, Kinga Winiarczyk, Katarzyna Szyszka-Barth, Katarzyna Reszka, Kamila Wojas-Krawczyk, Janusz Milanowski, Maciej Krzakowski
Journal: Journal of Thoracic Oncology (2017)
P1.08-078 Does Surgery Have Real Benefit in Resectable Oligometastatic NSCLC?
Authors: Oleg Pikin, Andrey Ryabov, Vladimir Glushko, Konstantin Kolbanov, Ali Amiraliev, Dmitriy Vursol, Vladimir Bagrov, Vitaliy Barmin
Journal: Journal of Thoracic Oncology (2017)
P98 An 18 (± 6) month follow up study of cognitive function in adults with Cystic Fibrosis Related Diabetes (CFRD)
Authors: HK Chadwick, A Morton, L Dye, CL Lawton, MW Mansfield, D Peckham
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Cognitive impairments have been observed in people with type 1 and 2 diabetes. People with cystic fibrosis (CF) who have developed CF related diabetes (CFRD) also show some degree of impairment relative to healthy controls. The aim of this study was to examine cognitive function in people with CFRD after an 18 (± 6) month period to assess any change in performance. <h3>Method</h3> Adult (&gt;16 years old), pancreatic insufficient patients with insulin treated CFRD registered to a large UK CF unit who had adequate verbal and written English were eligible. Cognitive performance was assessed using parallel versions of tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB). Subjective ratings of sleep, stress, mood, cognitive performance and minor daily cognitive errors were also collected. At baseline, 67 people were tested; 49 non transplanted and 18 post transplantation patients. Twelve patients were lost to follow-up. To date, 43 people have been retested after an 18 (± 6) month period; 35 non transplanted and 8 post transplantation patients. <h3>Results</h3> At follow up, blood glucose levels were significantly lower during testing (reflecting better glycaemic control in some patients) and people reported significantly fewer occurrences of minor daily cognitive errors within the past 6 months. There was no change in performance between baseline and follow up on tests of motor function, visual memory and new learning, immediate pattern recognition, working memory and mental flexibility. On tests of immediate and delayed verbal memory, delayed pattern recognition and processing speed, performance had significantly improved at follow up. <h3>Conclusion</h3> Cognitive function is impaired in people with CFRD but remains stable over an 18 (±6) month period. Deficits in cognitive performance may impact upon quality of life and ability to adhere to treatment.
P3.02b-012 Longitudinal Monitoring of ctDNA EGFR Mutation Burden from Urine Correlates with Patient Response to EGFR TKIs: A Case Series
Authors: Nishan Tchekmedyian, Raja Mudad, Eric Haura, Fernando Blanco, Victoria Raymond, Mark Erlander, Jordan Garst, David Berz
Journal: Journal of Thoracic Oncology (2017)
MA09.01 Dual Blockade of PD-1 and C5a/C5aR Synergistically Protects against Non-Small Cell Lung Cancer Tumor Growth
Authors: Daniel Ajona, Sergio Ortiz, Haritz Moreno, Silvestre Vicent, Luis Montuenga, Fernando Lecanda, Ruben Pio
Journal: Journal of Thoracic Oncology (2017)
The Impact of NOD2/CARD15, TLR and IL23R Polymorphisms on the Incidence of Infectious Complications in Allo-HSCT Recipients.
Authors: Alexandra Maria Holowiecka-Goral, Sebastian Giebel, Jerzy Wojnar, Elzbieta Pietruszka, Agnieszka Karolczyk, Anna Soja, Tomasz Czerw, Jerzy Holowiecki, Malgorzata Krawczyk-Kulis, Miroslaw Markiewicz, Wlodzimierz Mendrek, Beata Stella-Holowiecka, Slawomira Kyrcz-Krzemien
Journal: Blood (2008)
P201 Integrating patient support groups into respiratory care pathways
Authors: M McKevitt, J Bacon, R Merritt
Journal: Thorax (2016)

<h3>Strategy for change</h3> The British Lung Foundation wanted to test if integrating respiratory support groups into the local pathway produced a better understanding of health care services available and lung disease; increased medicine management and compliance; increased patient confidence and development of new skills. Did it also impact on control of health and demand on NHS services including unplanned hospital admissions? <h3>Assessment</h3> The aim of this evaluation was two-fold: A process evaluation: to look at the barriers and facilitators to integrating a support group into a respiratory care pathway. An outcome, impact and economic evaluation: to measure impact on both physical and mental wellbeing and the benefits to NHS services, clinicians and commissioners <h3>Methodology</h3> We employed validated questionnaires to measure physical, psychological and general wellbeing outcomes in participants. These were disseminated to control and test group at baseline and at 6 monthly intervals. Impact on NHS services was self-reported via telephone interviews with patients. <h3>Effects of changes</h3> There was a self-reported 42% reduction in unplanned GP visits and a 57% reduction in unplanned hospital admissions compared to standard support groups. People living with a lung condition who attended any type of support group had significantly greater quality of life at 6 months compared to control. Those attending groups maintained quality of life throughout the study whereas quality of life decreased by more than 20% for patients in control group. Those attending standard groups maintained self-efficacy whereas there was a decrease of 17% for those in control group. For each pound invested in the integrated support groups there is a return of a minimum £3.43 and a maximum of £9.36. For each pound invested in the integrated groups, there is a net gain of £8.01 in social return. <h3>Lessons learnt</h3> Integrated respiratory patient support groups is a cost effective programme which has positive outcomes in terms of self-efficacy, health outcomes and wellbeing for attendees, providing cost savings and wider social benefits to local communities.
BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes
Authors: Frederik Damm, Chesnais Virginie, Laurianne Scourzic, Veronique Gelsi-Boyer, Aline Renneville, Francois Dreyfus, Sophie Park, Odile Beyne-Rauzy, Borhane Slama, Agnès Guerci-Bresler, Bruno Quesnel, Eric Solary, Aline schmidt-Tanguy, Stephane Cheze, Christian Rose, Thomas Prebet, Stephane de Botton, Norbert Vey, Claude Preudhomme, Daniel Birnbaum, Olivier A. Bernard, Michaela Fontenay, Olivier Kosmider
Journal: Blood (2012)
HLH (Hemophagocytic Lymphohistiocytosis) At a Tertiary Care Hospital, B J Wadia Hospital for Children,In Mumbai, India
Authors: Mukesh Manharlal Desai, Harvinder Iqbal Palaha, Snehal Desai, Manisha Madkaikar, Bharat Agarwal, Nitin Shah, Archana Swami, Kanjaksha Ghosh
Journal: Blood (2011)
OA02.02 Gremlin-1 is a Key Regulator of the Invasive Phenotype in Mesothelioma
Authors: Miao Yin, Mira Tissari, Jenni Tamminen, Irene Ylivinkka, Mikko Ronty, Kaisa Lehti, Marko Hyytiainen, Marjukka Myllarniemi, Katri Koli
Journal: Journal of Thoracic Oncology (2017)
OVERcome: An intervention study to improve sexual function in women with breast cancer.
Authors: I. Juraskova, S. Jarvis, K. Mok, M. Peate, B. Meiser, S. Mireskandari, M. Friedlander
Journal: Journal of Clinical Oncology (2011)

9066 Background: Sexual problems have been reported in up to 50% of breast cancer (BC) survivors, with vaginal dryness and dyspareunia the most common predictors of sexual dysfunction. Yet, only a few studies have explored non-hormonal strategies to alleviate sexual dysfunction. This pilot study prospectively evaluated acceptability and efficacy of a novel Olive Oil Vaginal Exercise and Replens (OVER)-come intervention involving: i) pelvic floor muscles (PFM) relaxation exercises to prevent and manage pelvic floor dysfunction, ii) a vaginal moisturizer (Replens) to alleviate vaginal dryness, and iii) olive oil as a lubricant during intercourse, in women with sexual difficulties following adjuvant BC treatment. Methods: Of the 37 women enrolled (84% response rate), 26 and 18 completed Week 12 and 26 follow-ups, respectively. Women were instructed to apply Replens 3 times/week, perform PFM exercises twice/day, use olive oil during intercourse as required, and complete a weekly compliance diary. The PFM intervention was administered by a trained pelvic floor physiotherapist at Weeks 0 (T0) and 4 (T1) and follow-ups at Weeks 12 (T2) and 26 (T3). At each time point, women completed validated measures of sexual functioning (SAQ, VAS-DYSPAR), quality of life (FACT-B), and distress (HADS); whilst the physiotherapist recorded objective measures of PFM functioning using Peritron vaginal manometer and Kontinence PFM surface electromyographic. Results: Women reported significant improvement in overall sexual functioning (T0-T1 and T0-T2: p<.001; T0-T3: p=.01), sexual satisfaction (T0-T1 and T0-T2: p=.005; T0-T3: p=.01), and degree of dyspareunia (T0-T1; T0-T2; T0-T3: p<.001). Maximal benefits of the intervention were noted by T2, with a plateau effect observed thereafter. Trends in improvement in quality of life were found at T2 (p=.06) and T3 (p=.09). The majority of women found the intervention acceptable, with PFM exercises (94%), Replens (88%), and olive oil (78%) rated as helpful. Conclusions: OVERcome appears to be an effective and safe intervention for women with physical sexual problems following BC treatment. An unexpected incidence of vaginal stenosis was found during initial screening, requiring further research.
P2.01-082 Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma
Authors: Yuqing Lou, Yanwei Zhang, Rong Li, Ping Gu, Liwen Xiong, Hua Zhong, Xueyan Zhang, Liyan Jiang, Wei Zhang, Baohui Han
Journal: Journal of Thoracic Oncology (2017)
MA01.02 Non-Invasive LuCED® Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with Drugs Such as Iloprost
Authors: Michael Meyer, Rahul Katdare, Chris Presley, David Wilbur, David Steinhauer, Jianming Liang, Javier Zulueta, Robert Keith, York Miller, Wilbur Franklin, Grgory Yang, Jon Hayenga, Alan Nelson
Journal: Journal of Thoracic Oncology (2017)
Bar code app aims to cut sugar intake
Authors: Jacqui Wise
Journal: BMJ (2017)

Public Health England (PHE) has launched a Sugar Smart app to help parents clearly see how much sugar everyday food and drink contains, after research showed that children consume half of their daily recommended sugar intake at breakfast alone.

PHE said that it had analysed data from its annual National Diet and Nutrition Survey and found that children in England consume on average more than 11 g of sugar at breakfast, equal to almost three sugar cubes.1

The recommended daily maximum intake of added sugar is 19 g (five sugar cubes) for children aged 4 to 6, 24 g (six sugar …
CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control
Authors: Antonella Zucchetto, Chiara Caldana, Riccardo Bomben, Erika Tissino, Francesca Maria Rossi, Dania Benedetti, Michele Dal Bo, Davide Rossi, Francesco Zaja, Gabriele Pozzato, Francesco Di Raimondo, Gianluca Gaidano, Giovanni Del Poeta, Valter Gattei
Journal: Blood (2012)
BMI at diagnosis and adverse outcomes among men with malignant testicular germ cell tumors.
Authors: Sarah C Markt, Rowan Miller, Elizabeth O'Donnell, Laurence Albiges, Brandon David Bernard, Carlos Lago-Hernandez, Stephanie A. Curreri, Alexi A. Wright, Clair Beard, Christopher Sweeney
Journal: Journal of Clinical Oncology (2015)

400 Background: Previous studies evaluating the relationship between measures of anthropometry, such as body mass index (BMI), and risk of testicular cancer have been conflicting, with most finding null or inverse associations. Methods: We conducted a retrospective review of 960 germ cell tumors among patients treated at the Dana-Farber Cancer Institute (DFCI) between 1997 and 2012 with information on BMI. BMI at diagnosis, tumor characteristics, IGCCC classification, treatment, relapse and cause of death was ascertained from electronic medical record review. We divided the men and conducted the analyses separately for two groups: 1) men who presented as clinical stage 1 (CS1), and 2) men who presented with metastases or were CS1 at diagnosis and developed metastases (lifemets). We conducted logistic regression to evaluate the association between BMI and characteristics at diagnosis, and Cox proportional hazards regression to investigate the risk of relapse and testicular cancer death. Results: 65% of men (n=628) were overweight or obese at diagnosis. We did not find an association between BMI and tumor characteristics at baseline, such as histology, lymphovascular invasion, or tumor size for either group. Among CS1 patients, men who were overweight or obese had a non-statistically significant reduced risk of relapse compared to men who were normal weight (HR: 0.83, 95% CI: 0.53-1.30). Among the lifemets group, 16% of men relapsed (n=83) and 8% died of testicular cancer (n=43). Although not statistically significant, men who were overweight or obese were less likely to present with intermediate (OR = 0.77, 95 CI: 0.39-1.52) and poor (OR = 0.66, 95% CI: 0.36-1.20) rather than good risk disease when compared to men with normal BMI. After adjusted for confounding variables, BMI was not associated with risk of relapse (HR: 0.94, 95% CI: 0.59-1.51) or risk of testicular cancer death (HR: 1.00, 95% CI: 0.54-1.84) among the lifemets group. Conclusions: We did not find an association between BMI at diagnosis and tumor characteristics at baseline, or risk of relapse or testicular cancer death among men with testicular cancer.